April 15, 2019
The health ministry will report its plan to approve Takeda Pharmaceutical’s inflammatory bowel disease medicine Entyvio (vedolizumab) for an additional indication of Crohn’s disease (CD) at a key advisory panel meeting on April 26. Entyvio, a humanized IgG1 monoclonal antibody...read more